Sickle Cell Anemia Gene Therapy

By: Candace Kesselring

See original here:
Sickle Cell Anemia Gene Therapy - Video

Recommendation and review posted by Bethany Smith

PUBLIC RELEASE DATE:

17-Nov-2014

Contact: Nik Papageorgiou n.papageorgiou@epfl.ch 41-216-932-105 Ecole Polytechnique Fdrale de Lausanne @EPFL_en

Chronic myeloid leukemia develops when a gene mutates and causes an enzyme to become hyperactive, causing blood-forming stem cells in the bone marrow to grow rapidly into abnormal cells. The enzyme, Abl-kinase, is a member of the "kinase" family of enzymes, which serve as an "on" or "off" switch for many functions in our cells. In chronic myeloid leukemia, the hyperactive Abl-kinase is targeted with drugs that bind to a specific part of the enzyme and block it, aiming to ultimately kill the fast-growing cancer cell. However, treatments are often limited by the fact that the cancer cells can adapt to resist drugs. EPFL scientists have identified an alternative part of Abl-kinase on which drugs can bind and act with a reduced risk of drug resistance. Their work is published in Nature Communications.

Abl-kinase and leukemia

Abl-kinase can turn "on" molecules that are involved in many cell functions including cell growth. In chronic myeloid leukemia, the chromosome that contains the gene for Abl-kinase swaps a section with another chromosome, causing what is known as the "Philadelphia chromosome". When this mutation takes place in the blood stem cells in the bone marrow, Abl-kinase fuses with another protein, turning into a deregulated, hyperactive enzyme. This causes large numbers of blood-forming stem cells to grow into an abnormal type of white blood cell, which gives rise to chronic myeloid leukemia.

To treat this type of leukemia we use drugs that specifically bind and block a part of Abl-kinase called the "active site". As the name suggests, this is the part of the enzyme that binds molecules to turn them on. Therefore, blocking the active site with a drug stops the hyperactivity of Abl-kinase caused by the Philadelphia mutation and slow down or even abolishes the production of abnormal cancerous blood cells. The problem is that targeting the active site of Abl-kinase often causes the cancer cells to adapt and develop drug resistance, making them harder to kill.

An indirect path against resistance

A team of researchers led by Oliver Hantschel at EPFL (ISREC) has now discovered a new way to indirectly inhibit the activity of Abl-kinase. The scientists systematically made small, strategic mutations to Abl-kinase that caused its 3D structure to change. Then they tested each mutant version of the enzyme to see if its function would change.

Hantschel's team built on previous studies showing that Abl-kinase is indirectly controlled by another part of itself called the "SH2 region", which is located close to the active site. Normally, the SH2 region regulates the active site by opening and closing it. But under the Philadelphia mutation, that regulation is lost. What the scientists discovered was that when the Philadelphia mutation takes effect, the SH2 region actually "clamps" open the active site of Abl-kinase and forces it to go into overdrive.

Read the original here:
A new approach to fighting chronic myeloid leukemia

Recommendation and review posted by Bethany Smith

NOTRE DAME - You could be a life saver!

On Friday, November 21, 2014, the Saint Mary's College student club SMC Stands Up To Cancer will hold a bone marrow registration drive on campus.

It'll take place from 11am to 3pm in Reignbeaux Lounge in Le Mans Hall. For a campus map click here.

To participate, you must be between the ages of 18 and 44. It's completely painless to sign up, requiring just a swab of the inside of your cheek to get a sample of cells.

Your genetic information will be added to the Be the Match marrow database, which searches for possible matches for blood cancer patients. Suitable donors can provide bone marrow or peripheral blood stem cells to patients, saving lives.

This will be the second annual bone marrow drive held on Saint Mary's campus. Typically, one person in 540 is a match for a patient with a blood cancer. But a match surfaced out of the 50 registered on campus at the last drive. Allison Lukomski '16, a communicative sciences and disorders major, was a match for a female cancer patient. Lukomski donated peripheral blood stem cells over fall break through a non-surgical procedure.

The bone marrow registration event comes on the heels of the Pink Party Zumbathon, hosted by SMC Stands Up to Cancer, which raised money for cancer research through the national organization Stand Up To Cancer.

Read more from the original source:
Bone marrow registration drive to be held at Saint Mary's College

Recommendation and review posted by Bethany Smith

A large-scale trial conducted in India has shown that stem cell therapy does not work in stroke patientsREUTERS

A study conducted on 120 patients in India has shown that stem cell treatment is not effective in treating paralysis resulting from a stroke.

The research which is thefirst large-scale study conducted in Indiacompared outcomes in those treated with stem cells to others and found no difference, reports Down to Earth.

While 60 patients with some form of disability of limbs caused by a stroke were given conventional treatment, an equal number received bone marrow stem cells in addition. All had experienced a stroke 3-4 weeks before the trial.

"We found that at the end of the first month, patients with stem cells showed more improvement compared to the control group. But at the end of the third month and one year, there was no difference," said Kameshwar Prasad, head, Department of Neurology, All India Institute of Medical Sciences (AIIMS), who led the study.

On an average 280 million bone marrow cells were injected, of which blood forming stem cells were around 2.9 million per patient.

The average age of patients in the study was around 50.

The study, published in the current issue of American journal Stroke, was conducted at AIIMS in New Delhi and four other hospitals covering four cities.

The study comes when many others have been suggesting that stem cells could help treat paralysis in stroke patients. The earlier study was done on a small number of patients as compared to the AIIMs study.

More research needs to be done, before stem cells are used in therapy as in India, many private clinics are openly offering stem cell treatment for various diseases.

Continue reading here:
Stem Cells Treatment Not Useful In Stroke Patients Finds Indian Study

Recommendation and review posted by Bethany Smith

New York, New York (PRWEB) November 17, 2014

Beyond Batten Disease Foundation (BBDF) and the New York Stem Cell Foundation (NYSCF) have been selected as a national innovator by the Milken Institute and will present their breakthrough findings about juvenile Batten disease at the 6th annual Partnering for Cures, November 16-18 in New York City. The presentation will highlight the collaborative efforts of NYSCF, BBDF and Batten Disease Support and Research Association.

Craig and Charlotte Benson established Beyond Batten Disease Foundation in August 2008 after their then five-year-old daughter, Christiane, was diagnosed with juvenile Batten disease. Together with hundreds of families affected by Batten disease, and many more supporters who share their hope and resolve, they are working tirelessly to create a brighter future for Christiane, and all children with Batten disease.

Watch the Benson Family story:

https://beyondbatten.org/family-stories/the-benson-family-story/

Beyond Batten Disease and the New York Stem Cell Foundation hope to ramp up funding and partnerships to develop stem cell resources to investigate and explore new treatments and ultimately find a cure for juvenile Batten disease, a fatal illness-affecting children as they convene at the FasterCures, conference. The Washington, D.C.-based center of the Milken Institute will bring together nearly 1,000 medical research leaders, investors and decision-makers to forge the collaborations needed to speed and improve outcomes-driven R&D. NYSCF scientists have created the first iPS cells from a neurological disease and the first ever stem cell disease model from any disease. This discovery was named Time Magazine #1 breakthrough in 2008 because it was the first time anyone has made stem cells from a person with a disease and used them to produce the type of cell that degenerated in that patient. Again, in 2012 Time Magazine recognized the Beyond Batten Disease Foundations creation of a rate genetic disease test as a top ten medical breakthrough.

We know the genetic mutations associated with juvenile Batten disease. This partnership will result in stem cell models of juvenile Batten, giving researchers an unprecedented look at how the disease develops, speeding research towards a cure, said Susan L. Solomon, NYSCF Chief Executive Officer.

Working with NYSCF to generate functional neuronal subtypes from patients and families is a stellar example of one of our key strategies in the fight against juvenile Batten disease: creating resource technology with the potential to transform juvenile Batten disease research and accelerate our timeline to a cure, said Danielle M. Kerkovich, PhD, BBDF Principal Scientist.

Juvenile Batten disease begins in early childhood between the ages of five and ten. Initial symptoms typically begin with progressive vision loss, followed by personality changes, behavioral problems, and slowed learning. These symptoms are followed by a progressive loss of motor functions, eventually resulting in wheelchair use and premature death. Seizures and psychiatric symptoms can develop at any point in the disease.

Juvenile Batten disease is one disorder in a group of rare, fatal, inherited disorders known as Batten disease. Over 40 different errors (mutations) in the CLN3 segment of DNA (gene) have been attributed to juvenile Batten disease. The pathological hallmark of juvenile Batten is a buildup of lipopigment in the bodys tissues. It is not known why lipopigment accumulates or why brain and eventually, heart cells are selectively damaged. It is, however, clear that we need disease-specific tools that reflect human disease in order to figure this out and to build therapy.

See the article here:
Beyond Batten Disease Foundation and the New York Stem Cell Foundation Chosen as a National Innovator by the Milken ...

Recommendation and review posted by Bethany Smith

Stem Cell Therapy for Labrador Retriever with Ruptured Tendon
Marc Smith DVM of Natchez Trace Veterinary Services and Pet-Tao Pet Foods explains how he utilizes VetraGenics Stem Cell Therapy to regenerate tissue and heal the tendon.

By: Marc Smith

Visit link:
Stem Cell Therapy for Labrador Retriever with Ruptured Tendon - Video

Recommendation and review posted by Bethany Smith

Contact Information

Available for logged-in reporters only

Newswise DALLAS November 17, 2014 Using next generation gene sequencing techniques, cancer researchers at UT Southwestern Medical Center have identified more than 3,000 new mutations involved in certain kidney cancers, findings that help explain the diversity of cancer behaviors.

These studies, which were performed in collaboration with Genentech Inc., identify novel therapeutic targets and suggest that predisposition to kidney cancer across species may be explained, at least in part, by the location of tumor suppressor genes with respect to one another in the genome, said Dr. James Brugarolas, Associate Professor of Internal Medicine and Developmental Biology, who leads UT Southwesterns Kidney Cancer Program at the Harold C. Simmons Cancer Center.

The scientists findings are outlined in separate reports in the Proceedings of the National Academy of Sciences and Nature Genetics.

More than 250,000 individuals worldwide are diagnosed with kidney cancer every year, with lifetime risk of kidney cancer in the US estimated at 1.6 percent. Most kidney tumors are renal cell carcinomas, which when metastatic remain largely incurable.

Researchers with UT Southwesterns Kidney Cancer Program had previously identified a critical gene called BAP1 that is intimately tied to kidney cancer formation. Their latest research shows how BAP1 interacts with a second gene, VHL, to transform a normal kidney cell into a cancer cell, which in part appears to be based on the two genes close proximity in humans, said Dr. Brugarolas, a Virginia Murchison Linthicum Endowed Scholar in Medical Research.

The newest findings suggest that the transformation begins with a mutation in one of the two copies of VHL, which is the most frequently mutated gene in the most common form of kidney cancer, clear cell type, which accounts for about 75 percent of kidney cancers. The VHL mutation is followed by a loss of the corresponding chromosome arm containing the second copy of VHL, as well as several other genes including PBRM1 and BAP1. This step eliminates the remaining copy of VHL and along with it, one of the two copies of PBRM1 and BAP1, two important genes that protect the kidney from cancer development. The subsequent mutation of the remaining copy of BAP1 leads to aggressive tumors, whereas mutation of the remaining copy of PBRM1 induces less aggressive tumors, said Dr. Payal Kapur, a key investigator of both studies who is an Associate Professor of Pathology and Urology, and the Pathology co-Leader of the Kidney Cancer Program.

This model also explains why humans born with a mutation in VHL have a high likelihood of developing kidney cancer during their life time. In these individuals, all kidney cells are already deficient for one VHL copy and a single deletion eliminates the second copy, along with a copy of BAP1 and PBRM1. In contrast, in other animals, these three genes are located on different chromosomes and thus more mutational events are required for their inactivation than in humans. Consistent with this notion, when UT Southwestern researchers mutated VHL and BAP1 together, kidney cancer resulted in animals.

In a second collaborative study with Genentech Inc., published in Nature Genetics, investigators implicated several genes for the first time in non-clear cell kidney cancer, a less common type that accounts for about 25 percent of kidney cancers. Researchers identified a gene signature that can help differentiate subtypes of non-clear cell tumors to better define their behavior. Specifically, the researchers characterized alterations from 167 human primary non-clear cell renal cell carcinomas, identifying 16 significantly mutated genes in non-clear cell kidney cancer that may pave the way for the development of novel therapies. The research team also identified a five-gene set that enabled molecular classifications of tumor subtypes, along with a potential therapeutic role for BIRC7 inhibitors for future study.

Read the original here:
Researchers Identify Gene Mutations and Process for How Kidney Tumors Develop

Recommendation and review posted by Bethany Smith

PUBLIC RELEASE DATE:

17-Nov-2014

Contact: Ron Gilmore rlgilmore1@mdanderson.org 713-745-1898 University of Texas M. D. Anderson Cancer Center @mdandersonnews

Scientists have found that altering members of the p53 gene family, known as tumor suppressor genes, causes rapid regression of tumors that are deficient in or totally missing p53. Study results suggest existing diabetes drugs, which impact the same gene-protein pathway, might be effective for cancer treatment.

The University of Texas MD Anderson Cancer Center investigation showed that, in vivo, the genes p63 and p73 can be manipulated to upregulate or increase levels of IAPP, a protein important for the body's ability to metabolize glucose. IAPP is found in some diabetes drugs already on the market.

The research findings were published in today's issue of Nature.

The study, led by Elsa R. Flores, Ph.D., associate professor of molecular and cellular oncology, centered on p63 and p73 because of the genes' ability to cause tumor regression or spur its growth due to their unique genetic makeup.

"P53 is altered in most human cancers and p53 reactivation suppresses tumors in vivo in mice. This strategy has proven difficult to implement therapeutically. We examined an alternative approach by manipulating the p53 family members, p63 and p73," said Flores.

Flores described two "warring" versions of p63 and p73 that are at odds when it comes to tumor suppression. One version, known as transactivation domain-bearing, is structurally and functionally similar to p53 in their ability to suppress tumors. The other version, which lacks this transactivation domain, actually prevents p53 from stopping tumor growth. Transactivation domains are specific regions within a protein known as a transcription factor that effect further downstream cellular responses.

"The p53 family interacts extensively in cellular processes that promote tumor suppression," said Flores. "Thus, a clear understanding of this interplay in cancer is needed to treat tumors with p53 alterations."

Continued here:
Metabolic 'reprogramming' by the p53 gene family leads to tumor regression

Recommendation and review posted by Bethany Smith

Contact Information

Available for logged-in reporters only

Note: This poster presentation, #310.07.J7, at the American Society for Neuroscience meeting, is titled Calorie restriction suppresses age-dependent gene expression and induces neuroprotective transcriptional signatures in the hippocampal CA1 region and will be on display from 8 a.m. to 12 noon EST, Monday, Nov. 17, in Exhibit Halls A-C at the Washington Convention Center in Washington, D.C.

Newswise The adage 'you are what you eat' has been around for years. Now, important new research provides another reason to be careful with your calories.

Neuroscientists at NYU Langone Medical Center have shown that calorie-reduced diets stop the normal rise and fall in activity levels of close to 900 different genes linked to aging and memory formation in the brain.

In a presentation prepared for the Society for Neuroscience annual meeting in Washington, D.C., on Nov. 17, researchers say their experimental results, conducted in female mice, suggest how diets with fewer calories derived from carbohydrates likely deter some aspects of aging and chronic diseases in mammals, including humans.

Our study shows how calorie restriction practically arrests gene expression levels involved in the aging phenotype how some genes determine the behavior of mice, people, and other mammals as they get old, says senior study investigator and NYU Langone neuroscientist, Stephen D. Ginsberg, PhD. Ginsberg cautions that the study does not mean calorie restriction is the fountain of youth, but that it does add evidence for the role of diet in delaying the effects of aging and age-related disease.

While restrictive dietary regimens have been well-known for decades to prolong the lives of rodents and other mammals, their effects in humans have not been well understood. Benefits of these diets have been touted to include reduced risk of human heart disease, hypertension, and stroke, Ginsberg notes, but the widespread genetic impact on the memory and learning regions of aging brains has not before been shown. Previous studies, he notes, have only assessed the dietary impact on one or two genes at a time, but his analysis encompassed more than 10,000 genes.

Ginsberg, an associate professor at NYU Langone and its affiliated Nathan S. Kline Institute for Psychiatric Research, says the research widens the door to further study into calorie restriction and anti-aging genetics.

For the study, female mice, which like people are more prone to dementia than males, were fed food pellets that had 30 percent fewer calories than those fed to other mice. Tissue analyses of the hippocampal region, an area of the brain affected earliest in Alzheimers disease, were performed on mice in middle and late adulthood to assess any difference in gene expression over time.

Here is the original post:
Calorie-Restricting Diets Slow Aging, Study Finds

Recommendation and review posted by Bethany Smith

PUBLIC RELEASE DATE:

17-Nov-2014

Contact: Kathryn Ryan kryan@liebertpub.com 914-740-2100 Mary Ann Liebert, Inc./Genetic Engineering News @LiebertOnline

New Rochelle, NY, November 17, 2014--In the future, as space exploration takes astronauts on longer missions and more female astronauts participate, "The Impact of Sex and Gender on Adaptation to Space" will become increasingly critical to astronaut safety and mission success, as explored in a special collection of articles published in Journal of Women's Health, a peer-reviewed publication from Mary Ann Liebert, Inc., publishers. The articles are available Open Access on the Journal of Women's Health website at http://online.liebertpub.com/toc/jwh/23/11.

In the Executive Summary, Drs. Saralyn Mark, Graham Scott, Dorit Donoviel, Lauren Leveton, John Charles, and Bette Siegel and Ms. Erin Mahoney from National Aeronautics and Space Administration (NASA), National Space Biomedical Research Institute (NSBRI), and Valador, Inc. provide an overview of six individual articles in the November issue of the Journal derived from the findings of workgroups formed to report on the current research related to sex- and gender-based differences in how humans adapt to spaceflight. Each workgroup and article focuses on a specific type of adaptation: cardiovascular, immunological, sensorimotor, musculoskeletal, reproductive, and behavioral.

In her Commentary, Dr. Mark remarks that in addition to ongoing missions for the purpose of space exploration and research, "NASA has promoted the development of the commercial space sector for the transport of payloads and eventually humans." The impact of sex and gender should influence "the development of equipment, machine-human interfaces, and countermeasures including the use of personalized medicine and genomics or -'astro-omics.'"

"Understanding sex and gender differences in physiological and psychological adaptation to space is increasingly important as the number of female astronauts increases," says Susan G. Kornstein, MD, Editor-in-Chief of Journal of Women's Health, Executive Director of the Virginia Commonwealth University Institute for Women's Health, Richmond, VA, and President of the Academy of Women's Health.

###

About the Journal

Journal of Women's Health, published monthly, is a core multidisciplinary journal dedicated to the diseases and conditions that hold greater risk for or are more prevalent among women, as well as diseases that present differently in women. The Journal covers the latest advances and clinical applications of new diagnostic procedures and therapeutic protocols for the prevention and management of women's healthcare issues. Complete tables of content and a sample issue may be viewed on the Journal of Women's Health website at http://www.liebertpub.com/jwh. Journal of Women's Health is the official journal of the Academy of Women's Health and the Society for Women's Health Research.

Read more from the original source:
New NASA and NSBRI report on sex and gender differences in adaptation to space flight

Recommendation and review posted by Bethany Smith

Neil Young is swearing off Starbucks lattes.

NEW YORK (CNNMoney)

Last week, the singer said on his website, that he was kicking his daily Starbucks latte habit because he claimed the coffee company had teamed up with Monsanto to sue Vermont for a new law on genetically engineered foods. Young called out to his fans to join a petition by the organization SumOfUs.

Now both companies are denying that they are part of the lawsuit.

Starbucks (SBUX) flatly denied, via Twitter, that the company has anything to do with the lawsuit. Vermont's new labeling law requires that companies identify whether its food products contain genetically modified organisms.

"Starbucks is not a part of any lawsuit pertaining to GMO labeling nor have we provided funding for any campaign," said Starbucks. "And Starbucks is not aligned with Monsanto to stop food labeling or block Vermont State law. The petition claiming that Starbucks is part of this litigation is completely false and we have asked the petitioners to correct their description of our position."

Related: Starbucks CEO tells Congress 'stop the polarization'

Monsanto (MON) spokeswoman Charla Marie Lord also said, "We are not in the lawsuit at all."

Both companies aren't named in the lawsuit, but they are both members of the Grocery Manufacturers Association, a lobbying group that filed the suit.

The group's spokesman Brian Kennedy confirmed that Starbucks is an "affiliate member" without any involvement in the group's lawsuit.

See the original post here:
Starbucks: Neil Young is wrong about boycott

Recommendation and review posted by Bethany Smith

Neil Young is swearing off Starbucks lattes.

NEW YORK (CNNMoney)

Last week, the singer said on his website, that he was kicking his daily Starbucks latte habit because he claimed the coffee company had teamed up with Monsanto to sue Vermont for a new law on genetically engineered foods. Young called out to his fans to join a petition by the organization SumOfUs.

Now both companies are denying that they are part of the lawsuit.

Starbucks (SBUX) flatly denied, via Twitter, that the company has anything to do with the lawsuit. Vermont's new labeling law requires that companies identify whether its food products contain genetically modified organisms.

"Starbucks is not a part of any lawsuit pertaining to GMO labeling nor have we provided funding for any campaign," said Starbucks. "And Starbucks is not aligned with Monsanto to stop food labeling or block Vermont State law. The petition claiming that Starbucks is part of this litigation is completely false and we have asked the petitioners to correct their description of our position."

Related: Starbucks CEO tells Congress 'stop the polarization'

Monsanto (MON) spokeswoman Charla Marie Lord also said, "We are not in the lawsuit at all."

Both companies aren't named in the lawsuit, but they are both members of the Grocery Manufacturers Association, a lobbying group that filed the suit.

The group's spokesman Brian Kennedy confirmed that Starbucks is an "affiliate member" without any involvement in the group's lawsuit.

Here is the original post:
Starbucks: Neil Young is wrong on boycott

Recommendation and review posted by Bethany Smith

PUBLIC RELEASE DATE:

17-Nov-2014

Contact: Megan Fellman fellman@northwestern.edu 847-491-3115 Northwestern University @northwesternu

Metastasis is bad news for cancer patients. Northwestern University scientists now have demonstrated a simple but powerful tool that can detect live cancer cells in the bloodstream, potentially long before the cells could settle somewhere in the body and form a dangerous tumor.

The NanoFlare technology is the first genetic-based approach that is able to detect live circulating tumor cells out of the complex matrix that is human blood -- no easy feat. In a breast cancer study, the NanoFlares easily entered cells and lit up the cell if a biomarker target was present, even if only a trace amount. The NanoFlares are tiny spherical nucleic acids with gold nanoparticle cores outfitted with single-stranded DNA "flares."

"This technology has the potential to profoundly change the way breast cancer in particular and cancers in general are both studied and treated," said Chad A. Mirkin, a nanomedicine expert and a corresponding author of the study.

Mirkin's colleagues C. Shad Thaxton, M.D., and Chonghui Cheng, M.D., both of Northwestern University Feinberg School of Medicine, are also corresponding authors.

The research team, in a paper to be published the week of Nov. 17 by the Proceedings of the National Academy of Sciences (PNAS), reports two key innovations:

"Cancers are very genetically diverse, and it's important to know what cancer subtype a patient has," Mirkin said. "Now you can think about collecting a patient's cells and studying how those cells respond to different therapies. The way a patient responds to treatment depends on the genetic makeup of the cancer."

Mirkin is the George B. Rathmann Professor of Chemistry in the Weinberg College of Arts and Sciences and professor of medicine, chemical and biological engineering, biomedical engineering and materials science and engineering.

Read more here:
First genetic-based tool to detect circulating cancer cells in blood

Recommendation and review posted by Bethany Smith

By LINDSEY TANNER AP Medical Writer

CHICAGO (AP) - A large study of gay brothers adds to evidence that genes influence men's chances of being homosexual, but the results aren't strong enough to prove it.

Some scientists believe several genes might affect sexual orientation. Researchers who led the new study of nearly 800 gay brothers say their results bolster previous evidence pointing to genes on the X chromosome.

They also found evidence of influence from a gene or genes on a different chromosome. But the study doesn't identify which of hundreds of genes located in either place might be involved.

Smaller studies seeking genetic links to homosexuality have had mixed results.

The new evidence "is not proof but it's a pretty good indication" that genes on the two chromosomes have some influence over sexual orientation, said Dr. Alan Sanders, the lead author. He studies behavioral genetics at NorthShore University HealthSystem Research Institute in Evanston, Illinois.

Experts not involved in the study were more skeptical.

Neil Risch, a genetics expert at the University of California, San Francisco, said the data are statistically too weak to demonstrate any genetic link. Risch was involved in a smaller study that found no link between male homosexuality and chromosome X.

Dr. Robert Green, a medical geneticist at Harvard Medical School, called the new study "intriguing but not in any way conclusive."

The work was published Monday by the journal Psychological Medicine. The National Institutes of Health paid for the research.

Read more:
Study suggests genetic link for male homosexuality

Recommendation and review posted by Bethany Smith

Lindsey Tanner, The Associated Press Published Monday, November 17, 2014 9:27AM EST Last Updated Monday, November 17, 2014 10:42AM EST

CHICAGO -- A large study of gay brothers adds to evidence that genes influence men's chances of being homosexual, but the results aren't strong enough to prove it.

Some scientists believe several genes might affect sexual orientation. Researchers who led the new study of nearly 800 gay brothers say their results bolster previous evidence pointing to genes on the X chromosome.

They also found evidence of influence from a gene or genes on a different chromosome. But the study doesn't identify which of hundreds of genes located in either place might be involved.

Smaller studies seeking genetic links to homosexuality have had mixed results.

The new evidence "is not proof but it's a pretty good indication" that genes on the two chromosomes have some influence over sexual orientation, said Dr. Alan Sanders, the lead author. He studies behavioural genetics at NorthShore University HealthSystem Research Institute in Evanston, Illinois.

Experts not involved in the study were more skeptical.

Neil Risch, a genetics expert at the University of California, San Francisco, said the data are statistically too weak to demonstrate any genetic link. Risch was involved in a smaller study that found no link between male homosexuality and chromosome X.

Dr. Robert Green, a medical geneticist at Harvard Medical School, called the new study "intriguing but not in any way conclusive."

The work was published Monday by the journal Psychological Medicine. The National Institutes of Health paid for the research.

See the original post:
Study suggests genetic link for homosexuality; experts skeptical

Recommendation and review posted by Bethany Smith

What Is The Definition Of Transposition, genetics
Visit our website for text version of this Definition and app download. http://www.medicaldictionaryapps.com Subjects: medical terminology, medical dictionary, medical dictionary free download,...

By: Medical Dictionary Online

Link:
What Is The Definition Of Transposition, genetics - Video

Recommendation and review posted by Bethany Smith

The Sims 4: Perfect Genetics Legacy [Part 1] Getting Started
We have decided to take on the Legacy Challenge, but we are adding a little change to the concept. We are adding in the Perfect Genetics Challenge into the mix. With that in mind it changes...

By: Connor K Games

Link:
The Sims 4: Perfect Genetics Legacy [Part 1] Getting Started - Video

Recommendation and review posted by Bethany Smith

Mcpe Genetics Mod (Fly,Infinite Milk,Eat Grass)
Genetics Mod! I will make an update video if they add anything A like and/or comment would be much apreciated 🙂 mOD : http://mcpedl.com/molecular-genetics-mod/ Follow me! Twitter : https://twi...

By: Cheesey Knucles

Original post:
Mcpe Genetics Mod (Fly,Infinite Milk,Eat Grass) - Video

Recommendation and review posted by Bethany Smith

Genetics plays - Don #39;t Give Up
September 21, 2013 Teatro Coliseo, Buenos Aires, Argentina Official Facebook page https://www.facebook.com/geneticsband.

By: Genetics

Read the original post:
Genetics plays - Don't Give Up - Video

Recommendation and review posted by Bethany Smith

Gene Therapy- Channel 4 news
Anchor Josh Barnette interviews Sydney Brooks and Hunter White and talks about their groundbreaking research in the field of genetics.

By: Hunter White

See the article here:
Gene Therapy- Channel 4 news - Video

Recommendation and review posted by Bethany Smith

Dr Zwerling on Gene Therapy
Ian #39;s school project.

By: Ian Zwerling

Read the rest here:
Dr Zwerling on Gene Therapy - Video

Recommendation and review posted by Bethany Smith

http://clinicaltrials.gov/ct2/show/record/NCT02176317 Umbilical cord blood (UCB) has been shown to lessen the clinical and radiographic impact of hypoxic brain injury and stroke in animal models and in infants with hypoxic ischemic encephalopathy. UCB also engrafts and differentiates in the brain, facilitating neural cell repair in animal models and human patients with inborn errors of metabolism undergoing allogeneic, unrelated donor UCB transplantation. Infusion of autologous UCB does not require immunosuppression and has been shown to be safe in young children with brain injuries such as cerebral palsy and stroke. In this study, the investigators hypothesize that infusion of a patients own umbilical cord blood cells (UCB) can offer neural protection/repair in the brain and reduction of inflammation associated with this disorder.

DUKE STEM CELL AUTISM TRIAL

Theres a lot of skepticism surrounding this trial using cord blood stem cells to treat autism. Apparently, the concerns are:

1. Autism is a name given to a whole host of diseases yet to be named, ie. many different symptoms. Stem cells are part of the natural healing system in the body. They are smart and migrate to fix damaged tissue and cells. Stem cells work within your body in conjunction with your physiology. You can try to train and control them but they have a mind of their own. For ex: When cardiac stem cells are injected into the heart, they often finish their work and then migrate down to the Pancreas and fix it. IV implantation is very much in keeping with this idea and relies on the stem cells smart capabilities. On a certain level, we dont need to know what is broken. They do. A soldier is trained to respond to orders, then told what to do and they damn well do it. Marines are taught to adapt, improvise, overcome and often sent into battle with limited intel. When faced with an obstacle, they change their strategy and create a new one to succeed. Both are very valuable. Stem cells are born Marines.

2. We dont know what causes Autism so we cant treat it. The people saying we dont know what causes Autism are the same people who knew cardiac cells dont regenerate, central nervous system cells dont regenerate, only Embryonic stem cells have value, Margarine is better than Butter, etc. Wrong, wrong, wrong, wrong.

There are more things in heaven and earth, Horatio, Than are dreamt of in your philosophy. Hamlet (1.5.167-8), Hamlet to Horatio

Our knowledge is incredibly limited. As time goes on, we learn more and everything we held as inviolate becomesviolated. Taking into consideration that everything we know will be proven wrong in a few decades and then wrong again in another few after that as we learn morepeople should probably stop blocking treatments because of what they know or in this case, dont know.

This just popped up and I had to add it. Regulation of developmental gene expression occurs in the reverse order to that expected http://phys.org/news/2014-07-developmental-gene-reverse.html modifications involving Polycomb proteins occur in a manner that contradicts existing models.

3. Stem cells cant make it into the brain where the damage is. This is a test for safety of stem cells in Autistic children so efficacy is only a secondary consideration. Lets see if they tolerate a small amount of stem cells first before giving them a full dose, though I see no reason why they wouldnt. Duke U. is where a number of successful pediatric cord blood/Cerebral Palsy trials were held. http://repairstemcell.wordpress.com/2012/04/10/cerebral-palsy-and-stem-cells/ CP involves the brain. Stem cells have a history of success with Ataxia, Traumatic Brain injury, etc. etc.

Conclusion:

See original here:
The Stem Cell Blog | Adult Stem Cell Patient Empowerment

Recommendation and review posted by simmons

Beverly Hills, California (PRWEB) November 17, 2014

Veteran television and movie actor Darius McCrary has received a revolutionary stem cell procedure for his painful knee and ankle. The regenerative medicine procedure with stem cells was performed by Dr. Raj, a top orthopedic doctor in Beverly Hills and Los Angeles.

Darius McCrary is well known for his decade long stint on Family Matters as character Eddie Winslow. He won a Best Young Actor Award for this role along with movie roles in both Mississippi Burning and Big Shots. Currently, Darius appears along with Charlie Sheen in the show Anger Management.

While staying in tip top shape for his career, Darius has developed persistent pain in his right knee and ankle. Rather than seek a regular cortisone injection for pain relief or opt for surgery, he desired the ability to repair the joint damage and achieve pain relief. "I couldn't imagine being immobilized because of injury, so I opted for a stem cell procedure."

The procedures were performed by Dr. Raj, who is a prominent Beverly Hills orthopedic doctor with extensive experience in regenerative medicine. The procedure consisted of a combination of platelet rich plasma therapy along with amniotic derived stem cell therapy. Anecdotal studies are showing that the stem cell procedures for extremity joints allow patients to achieve pain relief and often avoid the need for potentially risky surgery.

Dr. Raj has performed over 100 stem cell procedures for patients who have degenerative arthritis or sports injuries. "Patients do extremely well with the procedures. Minimal risk and there's a huge potential upside!"

With an active acting career, Darius McCrary cannot afford to be distracted with chronic pain. "I'm looking forward to getting back in the gym and going hard without this pain," he stated excitedly. The procedure was filmed and can be seen on Dr. Raj's Facebook page.

To discuss stem cell procedures at Beverly Hills Orthopedic Institute and how they can benefit, call (310) 247-0466.

Read this article:
Veteran Actor Darius McCrary from Family Matters Receives Stem Cell Procedures with Dr. Raj in Beverly Hills

Recommendation and review posted by simmons

You no longer have to be Rich and famous to experience the Profound Healing effects and Intense Revitalizing and Anti-Aging benefits of MFIII (MF3) Live Cell Therapy - the best anti-aging product available in the world! Thanks to Swiss innovation and Technology, this amazing anti-aging product is now available for the first time in 70 years, and some refer to this scientific breakthrough in anti-aging and looking young as the Stem Cell in a Capsule.

Whether you are sick or experiencing chronic fatigue or just seeking the best Anti-aging and Skin Beauty supplement, everyone will benefit from the rejuvenation and regeneration of MFIII of Switzerland Live Cell Therapy. Best of all, it's acompletely Natural and Safe anti-aging solution, facilitatating and enhancing the body's ability to heal itself naturally, free from any side effects.

At last, you can feel younger, reduce cellular aging and feel full of vitality, energy, and dynamism in around 3-6 weeks with MFIII Switzerland hi-tech oral supplement formulation. MF III ( MF3) Sheep and Vegetal Placenta helps to awaken dormant cells inside the body, thereby enhancing the expression and function of existing cells, revitalizing and regenerating old and malfunctioning cells. This amazing anti-aging supplement offers what vitamins, minerals, hormones, chemicals and other typical treatments can't to worn out cells. It facilitates the processes and actual requirements for cellular functioning, mandatory for aged, hurt or sick organs and tissues to fix and regenerate, therefore providing amazing age-defying, health beauty benefits at the very same time.

Cell Treatment (or Live Cell Therapy) was first invented in an injectible form by Swiss surgeon Dr Paul Niehans in 1931. As you'll soon learn: Cell Therapy is essentially the forerunner of the better-known Human Stem Cell Therapy, which was invented in the 1960s based mostly on the principle of Cell Therapy.

Due to their intense health and beauty benefits but exceedingly high cost, Cell Therapy injections have for a while been a celebrity secret in protecting a young appearance and supporting critical health problems. Pope Pius XII was so happy with the treatment that he inducted Dr Paul Niehans, the deviser of Cell Therapy, into the Papal Academy of Science, making him the successor to the late Sir Alexander Fleming, the discoverer of penicillin.

Many celebrities, presidents and members of the Swiss Soccer World Cup team have benefited from Cell Therapy. President Eisenhower, Prime Minister Winston Churchill, and French General De Gaulle received it to maintain their powers of concentration and their physical endurance. Adenauer credited live cell therapy with giving him the energy to guide the Republic of Germany though he was more than ninety years old.

Charlie Chaplin claimed it enabled him to marry again and father kids after age seventy. Exclusive hospitals for the wealthy & famous in Switzerland have administered the Anti-Aging Cell Therapy to both western and oriental celebs, improving and lengthening their vigor and conserving their young appearance and capabilities.

Actress of "Law & Order"

"There is NO compromise for quality and effectivenes. I won't settle for anything else"

European Model

Read more:
Authorized MFIII (MF3) - Cell Placenta Therapy For Anti-Aging

Recommendation and review posted by Bethany Smith

e-cell: energy for life

The e-cell is a personal and portable 'bio-electronic' device that stimulates the bodys own natural healing processes. It utilises a unique programmed electromagnetic field, with each therapy card designed accordingly to meet specific tissue types and the healing stage of your injury. These Smart cards are available specifically for the Shoulder, Elbow, Wrist, Neck Mid back, Low Back, Hip, Knee, Ankle, Bone, and Vascular. Just 30 minutes a day will speed the recovery of those strains and pains you are suffering.

Using innovative technology originally developed by NASA scientists to simulate physical exercise for its astronauts, the e-cell has a proven record of results through extensive clinical trails over a 23 year period.

The e-cell replicates and amplifies the bodys own natural repair and regeneration process by simulating exercise at a cellular level. It encourages 'dormant' cells to absorb nutrients again, enabling them to repair thus resulting in the relieving of pain symptoms.

for more on this ground-breaking device including detailed information on the application of Therapy cards and purchasing options.

is the sole distributor of the e-cell in the UK and has nearly 35 years experience as a worldwide wholesale distributor and exporter of pharmaceutical and medical supplies.

Excerpt from:
e-cell ElectroMagnetic Therapy Energy cell portable drug ...

Recommendation and review posted by Bethany Smith